Jefferies initiates coverage of Mentari Therapeutics with buy rating, $30 target price
MTRI•Jefferies initiated coverage of Mentari Therapeutics with a buy rating and a $30 target price.
Related News
Valneva's IXCHIQ shows 94% seroresponse five years after single dose
VALN•
Constellation Energy Corp: CIBC raises target price to $346 from $343
CEG•
Ionis Pharmaceuticals: Needham cuts target price to $54 from $86
IONS•
Fidelity National Financial: Stephens raises target price to $56 from $50
FNF•
Onto Innovation Inc.: Jefferies cuts target price to $350 from $400
ONTO•